News | December 19, 2022
Shilpa Medicare introduces cancer drug Capecitabine 1000 MG dispersible tablet
The product is backed by required scientific proof and comparative bioequivalence studies
The product is backed by required scientific proof and comparative bioequivalence studies
The two-day event focused on the multi-faceted relationship of clinical research stakeholders and looked at bridging the academic and clinical research gap.
DSCO has requested WHO to share at the earliest with CDSCO the report on establishment of causal relation to death with the medical products in question etc.
The event is supported by the Ministry of Commerce & Industry, Government of India and CDSCO, Ministry of Health.
The Department of Health and Family Welfare updated the preparedness for transition to licensing of Class-A and Class-B medical devices with effect from 1st October, 2022 under Medical Devices Rules 2017
Pfizer’s Paxlovid is approved by US FDA for COVID treatment
The Allurion Program is suited for people who are unable to achieve their weight-loss goals by dieting alone or for those who do not want to, or cannot, undergo invasive surgery or endoscopy
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
Govt committed to supporting pharma companies with industry-friendly policies
Subscribe To Our Newsletter & Stay Updated
